HidradenitisSuppurativa PS_080417_Final

Background Hidradenitis Suppurativa (HS) – Disease State
Pathophysiology
Diagnosis References
Severity Assessments
Treatment 22. PR Newswire. AbbVie’s HUMIRA® (adalimumab) receives first and only U.S. Food and Drug Administration approval for moderate to severe
Self-test hidradenitis suppurativa. 2015. http://www.prnewswire.com/news-releases/abbvies-humira-adalimumab-receives-first-and-only-us-food-and-drug-
Abbreviations administration-approval-for-moderate-to-severe-hidradenitis-suppurativa-300141140.html. Accessed June 24, 2016.
Glossary
References 23. European Medicines Agency. First medicine recommended for approval for hidradenitis suppurativa. 2015.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/06/news_detail_002354.jsp&mid=WC0b01ac058004d5c1.
Accessed June 24, 2016

24. Humira® (adalimumab) prescribing information. North Chicago, IL: AbbVie Inc.; 2016.
25. Food and Drug Administration. Information for consumers (biosimilars). 2017.

https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications
/Biosimilars/ucm241718.htm. Accessed June 23, 2017
26. Patient Protection and Affordable Care Act. 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf.
Accessed May 19, 2016.
27. Food and Drug Adminitration. Information for healthcare professionals (biosimilars). 2017.
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/bio
similars/ucm241719.htm. Accessed June 23, 2017
28. Amgen. What are biosimilars. 2015. http://www.amgenbiosimilars.com/the-basics/what-are-biosimilars/. Accessed April 26, 2016.
29. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422-434.
30. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a
randomized, double-blind, placebo-controlled crossover study. J Am Acad Dermatol. 2010;62:205-217.
31. Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol.
2010;49:950-955.
32. European Academy of Dermatology and Venereology. About EADV. https://www.eadv.org/about Accessed June 23, 2017.
33. American College of Rheumatology Glossary. Biologics. 2016. http://www.rheumatology.org/Learning
Center/Glossary/articleType/CategoryView/categoryId/7/B. Accessed April 1, 2016.
34. Crohn’s & Colitis Foundation of America. What is Crohn’s disease? 2016. http://www.ccfa.org/what-are-crohns-and-colitis/what-is-crohns-disease/.
Accessed February 18, 2016.
35. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and
clinical results. Br J Dermatol. 2008;159:997-1035.
36. Office of Disease Prevention and Health Promotion. Health-related quality of life and well-being. 2014.
https://www.healthypeople.gov/2020/about/foundation-health-measures/Health-Related-Quality-of-Life-and-Well-Being. Accessed March 28, 2016.
37. Raychaudhuri SP and Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun. 2014;48-49:128-133.

This material is for your information and/or training only. It cannot be shown to or otherwise used with members of the Healthcare Community.
Any links to external websites and the articles or content contained therein are included as part of this guidance. © 2017 Amgen Inc. All rights reserved.